SPECIAL FEATURES

CCR Translations

Therapeutic Oligonucleotides: The Road Not Taken
Cy A. Stein and Sanjay Goel
See commentary p. 6582

Molecular Pathways

The Role of Erythropoietin and Erythropoiesis-Stimulating Agents in Tumor Progression
Benjamin D. Hedley, Alison L. Allan, and Anargyros Xenocostas

TLX1-Induced T-cell Acute Lymphoblastic Leukemia
Kim De Keersmaecker and Adolfo A. Ferrando

CCR Focus

Antibody Conjugates: The Future Is Now
Susan E. Bates

Antibody Conjugate Therapeutics: Challenges and Potential
Beverly A. Teicher and Ravi V.J. Chari

Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
Robert J. Kreitman and Ira Pastan

Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
Martina Steiner and Dario Neri

Antibody-Drug Conjugates of Calicheamicin Derivative: Gentuzumab Ozogamicin and Inotuzumab Ozogamicin
Alejandro D. Ricart

Brentuximab Vedotin (SGN-35)
Jessica Katz, John E. Janik, and Anas Younes

CANCER THERAPY: PRECLINICAL

Tumor-Derived Autophagosome Vaccine: Induction of Cross-Protective Immune Responses against Short-lived Proteins through a p62-Dependent Mechanism
Christopher G. Twitty, Shawn M. Jensen, Hong-Ming Hu, and Bernard A. Fox

Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer
Ning Jin, Tianyin Jiang, David M. Rosen, Barry D. Nelkin, and Douglas W. Ball

The Novel Chemical Entity YTR107 Inhibits Recruitment of Nucleophosmin to Sites of DNA Damage, Suppressing Repair of DNA Double-Strand Breaks and Enhancing Radiosensitization
**CANCER THERAPY: CLINICAL**

6500 Significant Biological Role of Sp1 Transactivation in Multiple Myeloma

6510 Dicer-Mediated Upregulation of BCRP Confers Tamoxifen Resistance in Human Breast Cancer Cells

6522 EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies
Virginie Poindessous, Djamila Ouaret, Karima El Ouadrani, Aude Battistella, Virginie P. M/eglaphones, Nyam Kamsu-Kom, Ame/é Petitprez, Alexandre E. Escargueil, Pascale Boudou, Sylvie Dumont, Pascale Cervera, Jean-Francois F/éjour, Thierry Andr/é, Christophe Tournigand, Benoist Chibaudel, Aimery de Gramont, and Annette K. Larsen

6531 Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers
Roberta Rosa, Davide Melisi, Vincenzo Damiano, Roberto Bianco, Sonia Garofalo, Teresa Gelardi, Sudhir Agrawal, Federica Di Nicolantonio, Aldo Scarpa, Alberto Bardelli, and Giampaolo Tortora

**IMAGING, DIAGNOSIS, PROGNOSIS**

6542 High XRCC1 Protein Expression Is Associated with Poorer Survival in Patients with Head and Neck Squamous Cell Carcinoma

**PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE**

6550 Discriminant Analysis of 18F-Fluorothymidine Kinetic Parameters to Predict Survival in Patients with Recurrent High-Grade Glioma
Mirwais Wardak, Christiaan Schippers, Magnus Dahlbom, Timothy Cloughesy, Wei Chen, Nagiehetti Satyamurthy, Johannes Czernin, Michael E. Phelps, and Sung-Cheng Huang

6560 PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients
Tamara L. Lotan, Bora Gurel, Siobhan Sutcliffe, David Esopi, Wenman Liu, Junfeng Xu, Jessica L. Hicks, Ben H. Park, Elizabeth Humphreys, Alan W. Partin, Miosop Han, George J. Netto, William B. Isaacs, and Angelo M. De Marzo

6570 Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin
Ahmad A. Tarhini, Paul Frankel, Kim A. Margolin, Scott Christensen, Christopher Ruel, Janice Shipe-Spoteo, David R. Gandara, Alice Chen, and John M. Kirkwood

6580 A Phase I Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer

See article p. 6369

**PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE**

6590 Comparison of Continuous versus Categorical Tumor Measurement–Based Metrics to Predict Overall Survival in Cancer Treatment Trials
Ming-Wen An, Sunitha J. Mandrekar, Megan E. Branda, Shauna L. Hillman, Alex A. Adjei, Henry C. Pitot, Richard M. Goldberg, and Daniel J. Sargent
LETTERS TO THE EDITOR

KRAS rs61764370 in Epithelial Ovarian Cancer—Letter
Joanne B. Weidhaas and Frank J. Slack

KRAS rs61764370 in Epithelial Ovarian Cancer—Response
Harvey A. Risch, Andrew Berchuck, and Paul D.P. Pharoah; for the Ovarian Cancer Association Consortium

ABOUT THE COVER

The work by Poindessous and colleagues shows that inhibition of EGFR- and VEGF(R)-signaling by combinations of two small molecule tyrosine kinase inhibitors (TKI), afatinib and vargatetf, has synergistic activity in colorectal cancer models that are refractory to combinations of the monoclonal antibodies cetuximab and bevacizumab. Importantly, only the TKIs were able to attenuate the phosphorylation of intracellular EGFR- and VEGFR-receptors which was accompanied by the induction of apoptotic cell death as indicated by TUNEL staining (nuclear DNA in blue, apoptotic nuclei in white). This work provides a rationale for clinical trials of the afatinib and vargatetf combination, even in patients with mutant KRAS. For details, see the article by Poindessous and colleagues on page 6522 of this issue.